HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Currency exchange hits Abbott nutritionals: Negative effects from currency exchange help drive down Abbott Nutrition's international revenues from nutritional products by 1.9 percent to $615 million in the firm's fiscal 2009 second quarter, even as U.S. sales grow 10 percent to $668 million. The Abbott Park, Ill.-based company July 15 said a 10.3 percentage point loss from currency exchange slowed nutritional revenues. Its worldwide nutritional sales increased 4 percent despite an unfavorable 5.2 percent effect of exchange rates to $1.28 billion for the April-June period. A 12 percent surge in adult products drove U.S. nutritionals growth to $326 million. Internationally, pediatric formulas continued expanding, growing 3.6 percent, including exchange rate effects, to $354 million. John Thomas, VP of investor relations, said during a same-day earnings call that Abbott expects to launch next-generation Similac and Gain infant formulas in eight more countries this year. He said the reformulated Similac formula and its user-friendly packaging "have been very well received" by customers (1"The Tan Sheet" March 23, 2009)

You may also be interested in...



Abbott, Wockhardt Terminate Nutritional Business Deal

Pharmaceuticals and diagnostics giant Abbott and debt-ridden Indian drug maker Wockhardt call off their $130 million deal for a nutritional business announced less than a year ago

China-Biotics continues probiotics growth

New retail products sold in the firm's Shining outlets helped drive net sales up 35.5 percent to $15.4 million in the first quarter of fiscal 2010. Shanghai-based China-Biotics reported Aug. 17 that net income for the April-June also rose significantly, to $5.8 million from $3.2 million. Quarterly earnings per share grew to 34 cents from 19 cents, the firm said. Looking ahead, the probiotics manufacturer intends to slow retail expansion as it readies a new facility to begin trial production of bulk additives in its second quarter (1"The Tan Sheet" July 20, 2009). China-Biotics added it applied in July for patents for four probiotics-based yogurt products with China's State Intellectual Property Office and anticipates receiving patent certificates in about two years

Abbott gains Indian nutrition brands

With the acquisition of Mumbai-based Wockhardt Ltd. nutritionals firm and products including the Farex, Dexolac and Nusobee formula brands, Abbott takes the No. 2 spot in India's pediatric nutrition category. The company also gains Protinex, the adult protein supplement segment leader, Abbott said July 28. Abbott's $130 million purchase of Wockhardt and certain subsidiaries provides the Abbott Park, Ill.-based firm manufacturing and commercial infrastructure in India, said Executive VP of Global Nutrition Holger Liepmann. While Abbott has experienced robust nutritionals growth recently in China, Southeast Asia and Latin America, negative effects of currency exchange hurt global sales figures in its fiscal 2009 second quarter (1"The Tan Sheet" July 20, 2009)

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS136615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel